Alpha Cognition Inc. (OTC:ACOGF – Get Free Report) hit a new 52-week high on Monday . The company traded as high as C$8.91 and last traded at C$8.40, with a volume of 4246 shares trading hands. The stock had previously closed at C$8.60.
Alpha Cognition Stock Performance
The stock has a market cap of C$1.27 billion, a P/E ratio of -70.00 and a beta of 2.80. The stock’s 50-day moving average is C$1.05 and its 200-day moving average is C$0.71.
Alpha Cognition (OTC:ACOGF – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported C($0.01) earnings per share for the quarter, beating the consensus estimate of C($0.04) by C$0.03. On average, equities analysts forecast that Alpha Cognition Inc. will post -0.19 EPS for the current year.
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Alpha Cognition
- Stock Analyst Ratings and Canadian Analyst Ratings
- Rocket Lab is the Right Stock for the Right Time
- P/E Ratio Calculation: How to Assess Stocks
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Investing In Preferred Stock vs. Common Stock
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
